Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
Clinical Cancer Research.
Times cited: 38
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial.
British Journal of Haematology.
Times cited: 51